BMS-986094

Generic Name: BMS-986094

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₃₉N_₆O_₉P

CAS Number: 1234490-83-5

Unique Ingredient Identifier: 62F4AD749Y

Background: INX-08189 has been used in trials studying the treatment of Hepatitis C, HCV (Genotype 1), and Hepatitis C Virus.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Phase 2

Withdrawn

Conditions: Hepatitis C Virus

Interventions: Drug: Daclatasvir
Drug: BMS-986094
Drug: Placebo for BMS-986094
Drug: Ribavirin

First Posted Date: 2012-06-28

Last Posted Date: 2014-05-09

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01629732

Locations: 🇺🇸
Local Institution, Orlando, Florida, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy